<DOC>
	<DOCNO>NCT00006263</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine carboplatin , temozolomide , filgrastim treat patient newly diagnose recurrent high-grade glioma .</brief_summary>
	<brief_title>Carboplatin , Temozolomide , Filgrastim Treating Patients With Newly Diagnosed Recurrent High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient newly diagnose high-grade glioma treat temozolomide , carboplatin , filgrastim ( G-CSF ) . - Determine toxicity treatment regimen patient . - Determine rate tumor progression patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord disease category ( glioblastoma multiforme v anaplastic astrocytoma vs several high-grade mixed glioma ) . Patients receive carboplatin IV 4 hour day 1-2 ; oral temozolomide every 12 hour day 1-5 ; filgrastim ( G-CSF ) subcutaneously IV daily start early day 7 continue blood count recover . Treatment repeat every 28 day least 4 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 102-222 ( 17-37 per 6 stratum ) accrue study within 4 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose glioblastoma multiforme anaplastic astrocytoma Residual tumor postoperative MRI Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : Under 65 Performance status : Karnofsky Lansky 70100 % OR ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Hemoglobin least 8 g/dL ( transfusion allow ) Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGPT great 3 time ULN Renal : Age 5 year : Creatinine le 1.2 mg/dL Age 5 10 year : Creatinine le 1.5 mg/dL Age 10 15 year : Creatinine le 1.8 mg/dL Age 15 year : Creatinine le 2.4 mg/dL Cardiovascular : No myocardial infarction within past 6 month Other : No concurrent serious medical condition would preclude study Able tolerate oral medication No prior malignancy patient receive prior chemotherapy spinal irradiation No history severe allergic reaction platinumcontaining compound Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 72 hour since prior filgrastim ( GCSF ) Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Concurrent steroid tumorrelated cerebral edema allow No concurrent corticosteroid solely antiemetic purpose Radiotherapy : No prior concurrent radiotherapy Surgery : Recovered prior surgery No concurrent surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>